Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia | Synapse
February 8, 2026Open Access
Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia
Key Points
This study aims to assess the efficacy of a treatment regimen combining decitabine and low-dose idarubicin for pediatric patients with refractory or relapsed acute myeloid leukemia.
Conducted as a multicenter, prospective Phase II trial
Involved 101 evaluable pediatric patients with relapsed/refractory acute myeloid leukemia
Administered decitabine with low-dose idarubicin, cytarabine, and G-CSF
Demonstrated a response in a significant proportion of patients
Highlighted potential improvement in treatment outcomes for this vulnerable population
Detailed specific response rates and survival metrics in the full study outcomes
Abstract
No standard salvage regimen exists for relapsed/refractory (R/R) pediatric AML. In this prospective, multicenter Phase II trial, 101 evaluable patients (